Prof Dario Alessi

Dario received his BSc in Biochemistry from the University of Birmingham in 1988 and obtained a Ph.D. in 1991 for his work on the synthesis and use of spin-labelled ATP analogues to study muscle contraction under the joint supervision of Ian Trayer (University of Birmingham) and David Trentham FRS (National Institute of Medical Research, Mill Hill, London).  He then carried out postdoctoral research with Philip Cohen in the MRC PPU from 1991 to 1997, where he became fascinated by protein kinases and how they control almost all aspects of cell biology.

In 1998 Dario became a Programme Leader in the MRC PPU, and assumed the Directorship of the Unit in April 2012.  Dario has received many awards and honours, including the Colworth Medal in 1999 (Biochemical Society), membership of EMBO (2005), the EMBO Gold Medal (2005), and fellowship of the Royal Society of Edinburgh (2002), the Royal Society of London (2008), and the Medical Academy of Science (2012).

More about Dario

Dr Miratul Muqit

Miratul graduated in Medicine with Honours from the University of Edinburgh in 1997. He was awarded a prestigious Kennedy Scholarship to study Neurobiology at Harvard University undertaking Huntington’s disease research in Mel Feany’s laboratory in 2001. He obtained his PhD in 2007 from the UCL Institute of Neurology where he made a major contribution to the discovery of PINK1 kinase mutations in Parkinson’s disease under the supervision of Nicholas Wood FMedSci and David Latchman. In parallel he received clinical training at leading London teaching hospitals including the Hammersmith Hospital and the National Hospital for Neurology and Neurosurgery at Queen Square. He specialized in Movement Disorders under Andrew Lees FMedSci and Kailash Bhatia.

Miratul joined the MRC PPU as a Wellcome Trust Intermediate Clinical Fellow (Sponsor: Dario Alessi FRS) in 2008 to investigate how PINK1 mutations lead to neurodegeneration in Parkinson’s. He has been a Wellcome Trust Senior Clinical Fellow since 2013. Miratul has received multiple awards including the Queen Square Prize in Neurology (2006) and the Linacre Prize Lecture from the Royal College of Physicians (2013). He became a member of the EMBO Young Investigator Programme in 2017.

More about Miratul

Dr Esther Sammler

I am a clinician scientist with an interest in neurodegenerative conditions and how to accelerate the application of scientific basic research discoveries towards identifying biomarkers and hopefully treatments. After graduating from medical school and working in Germany, I entered the Scottish neurology training programme in 2009. In 2014, I obtained my PhD as a Wellcome Trust fellow supervised by Professor Dario Alessi FRS FRSE on the “Signalling pathway of the E3 ubiquitin ligase subunit FBXO7 and its role in hereditary Parkinsonism”. I was appointed consultant neurologist in NHS Tayside in 2016. My interest is in neurogenetics and Parkinson’s disease. For my research I continue to work in the MRC Protein Phosphorylation Unit.

More about Esther

Cells, energy control and Parkinson’s: The role of PINK1 and Parkin

Dr. Miratul Muqit


My research is directed at defining key pathways in cells that are linked to the development of Parkinson’s and harnessing this knowledge to generate new ideas to prevent and treat the condition. Major advances in genetics have provided clues as to the key molecules that control such pathways however there remain fundamental gaps in our understanding of how these genes function in cells. In my laboratory we have been focused on the PINK1 and Parkin genes that represent the commonest genetic cause of Parkinson’s in patients under the age of 45.

In my presentation I will discuss how the PINK1 and Parkin genes cooperate very closely in cells to protect us against damage to ‘mitochondria’ which are energy-producing centres of our cells. Our work has spanned very basic experiments in cells, but we have recently obtained very strong evidence in humans of the relevance of the PINK1-Parkin pathway to Parkinson’s.

Our work provides a framework for Clinicians to translate our knowledge and test our findings in patients both for the development of better diagnostics and therapies against Parkinson’s.

Bench to bedside Parkinson’s Research

Dr. Esther Sammler


The greatest unmet need in Parkinson’s are treatments that slow the relentless progression of its symptoms. The discovery of genetic changes in different genes that cause Parkinson’s have prompted new therapeutic approaches. LRRK2 is the most frequently mutated gene in Parkinson’s and LRRK2 inhibitor drugs have recently entered early clinical trial stages. However, many questions remain including markers of disease progression, biochemical markers for LRRK2 activation status and biomarkers for drug target engagement. These biomarkers will be necessary to confirm patient subgroups with high LRRK2 activity that might receive greater benefits from these therapies and ensure that the drug has the desired effect on the pathway targeted.

My talk will focus on a test that we have developed to measure LRRK2 activity in human peripheral blood and I will show very exciting data demonstrating the usefulness of this test.

For people interested in participating in research, I will also briefly mention a translational research project of mine (involving donating a blood sample) that will soon launch in the East and South East of Scotland.

LRRK2 in Parkinson’s

Prof. Dario Alessi


My laboratory is focused on deciphering the molecular causes of Parkinson’s. We believe that if we can comprehend what causes Parkinson’s, this will enable Researchers, Clinicians and Pharmaceutical Companies to work together to develop better ways to diagnose and treat the condition in the future. The approach we are taking is to study how mutations in certain genes cause Parkinson’s. One of the genes that we are working most on is called “LRRK2”. The LRRK2 gene is one of the most commonly mutated genes that causes familial inherited Parkinson’s. The LRRK2 gene encodes for a protein that is called the “LRRK2 enzyme”. Important research by our laboratory and others has shown that Parkinson’s mutations activate the LRRK2 enzyme.

This has led to the suggestions that drugs that target the LRRK2 enzyme could be developed for the better treatment of Parkinson’s. Excitingly, a company called Denali, based in San Francisco has recently launched the first clinical trials to test this idea. Several other companies are expected to initiate LRRK2 Parkinson’s trials soon.

These new drugs have the potential to slow down the progression of Parkinson’s.  

I will talk about the highlights of our recent research that have led to the discovery of how the LRRK2 enzyme works to control the activity of another set of enzymes called Rab.  I will describe recent work that has resulted in the discovery that mutation in several other genes that cause Parkinson’s, are also excitingly linked to the LRRK2 and Rab enzymes. Our work is revealing that LRRK2 is at the centre of a physiological network which is critical to understanding Parkinson’s. I will explain that with this increasing knowledge of the genetics and biology underlining Parkinson’s, I feel optimistic.

I believe that it is not unrealistic that with continued and expanded research efforts, major strides towards better treating Parkinson’s disease can be made in the coming years. Patient’s support and involvement in research is vital for success!

Unveiling some mechanisms that trigger Parkinson’s

The loss of the brain’s ability to produce dopamine is the cause of Parkinson’s disease.

50 years ago levodopa was developed, which supplies the brain with the missing dopamine, and it is still the gold standard for treating Parkinson’s. In order to fight not only the symptoms but also the disease itself, to slow down or stop its progression, the mechanisms that bring the production of dopamine to a standstill must be recognised.

Researchers at the University of Dundee have discovered some of these mechanisms and are thus feeding hope for a novel treatment of the causes of Parkinson’s disease.

The DRIG Spring Conference 2018 is dedicated to this topic.

The event is aimed at anyone with an interest in Parkinson’s disease – patients, carers, healthcare professionals or anyone interested in learning more about the disease. Participation in the conference is free, but registration is still required.

In addition to the conference contributions of renowned scientists and experts, there will be an interaction session during which participants can exchange directly with scientists and professionals and thus stimulate further research.

Date: June 26, 15:30 – 19:00
Location: Invercarse Hotel, 371 Perth Road, Dundee, DD2 1PG


Time Topic Speaker
15:30 Registration and refreshments, Interaction Session
16:00 Opening by Marc van Grieten (MvG) and
Introduction of John Minhinick (JM) as chair of the conference
16:05 Introduction of Prof Ken Bowler
From Edinburgh to Dundee: Research Interest Groups – a success story
Prof Ken Bowler
16:20 Introduction of MvG by JM
Perspective of a Person with Parkinson’s
16:30 Introduction of Prof Dario Alessi
LRRK2 in Parkinson’s
Facilitated Q&A / discussion
Prof Dario Alessi
17:10 Introduction of Dr. Esther Sammler
Bench to bedside Parkinson’s research
Facilitated Q&A / discussion
Dr. Esther Sammler
17:30 Break and Interaction Session
18:10 Introduction of Dr. Miratul Muqit
Cells, energy control and Parkinson’s: the role of PINK1 and Parkin
Facilitated Q&A / discussion
Dr. Miratul Muqit
18:30 Panel discussion and further Q&A
Panel: Ken Bowler, Dario Alessi, Esther Sammler and Miratul Muqit
18:55 Conclusion and closing remarks MvG
19:00 End of Event

Please register for the event